Showing results (51-60 of 93) with videos related to
Sort By:
Pageof 10
BMC Rheumatology|March 20, 2019
Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritisVibeke Strand, M Elaine Husni, Keith A Betts, et al.Infectious Diseases and Therapy|August 31, 2025
RSV Testing Patterns and Characteristics Associated with RSV Testing Among Adults Aged 50 Years or Older in the United StatesDavid Singer, Emily K Horn, Yan Wang, et al.Kidney Medicine|November 7, 2022
CKD Progression and Economic Burden in Individuals With CKD Associated With Type 2 DiabetesC Daniel Mullins, Kevin M Pantalone, Keith A Betts, et al.Journal of the American Academy of Dermatology|October 11, 2017
Poor early response to methotrexate portends inadequate long-term outcomes in patients with moderate-to-severe psoriasis: Evidence from 2 phase 3 clinical trialsKenneth B Gordon, Keith A Betts, Murali Sundaram, et al.Lung Cancer (Amsterdam, Netherlands)|April 24, 2021
Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancerDavid Waterhouse, Jenny Lam, Keith A Betts, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 25, 2012
Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness researchJames E Signorovitch, Vanja Sikirica, M Haim Erder, et al.Journal of Managed Care & Specialty Pharmacy|May 27, 2020
Model of Short- and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia AZheng-Yi Zhou, Karina Raimundo, Anisha M Patel, et al.Future Oncology (London, England)|April 14, 2021
Treatment patterns in patients with metastatic non-small-cell lung cancer in the era of immunotherapyDavid Stenehjem, Solomon Lubinga, Keith A Betts, et al.Current Medical Research and Opinion|October 31, 2014
One-year and long-term molecular response to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparisonJames E Signorovitch, Keith A Betts, William M Reichmann, et al.Journal of Comparative Effectiveness Research|January 14, 2021
Network meta-analysis of nivolumab plus ipilimumab in the second-line setting for advanced hepatocellular carcinomaNeehar D Parikh, Alexander Marshall, Keith A Betts, et al.Pageof 10